Table 1.

Antiviral Activities and Cytotoxicities of Compounds vs. Yellow Fever Virus.^a

Comp.	% Inhibitiona	GI50b (μM)	EC50c (μM)	TI
2	99.6	222.5 ± 35.0	2.83 ± 1.0	78
5a	< 50	NDd	NDd
5b	< 50	NDd	NDd
5c	< 50	NDd	NDd
5d	< 50	NDd	NDd
5e	< 50	NDd	NDd
5f	< 50	NDd	NDd
5g	< 50	NDd	NDd
5h	< 50	NDd	NDd
5i	−1672.6	NDd	NDd
5j	−8.2	NDd	NDd
5k	78.4	433.5 ± 23.3	35.7 ± 22.7	12
5l	< 50	NDd	NDd
5m	91.9	63.1 ± 6.4	2.8 ± 0.8	22
5n	−222.5	NDd	NDd
5o	−23.8	NDd	NDd
5p	−6.5	NDd	NDd
5q	98.6	41.5 ± 7.6	38.9 ± 8.2	1.1
5r	83.2	499.0 ± 0.9	34.3 ± 3.9	12
6a	< 50	NDd	NDd
6b	< 50	NDd	NDd
6c	93	26.5 ± 1.5	26	1
6d	81.9	407.5 ± 78.3	3.3 ± 2.1	121
6e	< 50	NDd	NDd
6f	< 50	NDd	NDd
6g	< 50	NDd	NDd
6h	< 50	NDd	NDd
6i	91.0	261.7 ± 27.9	10.6 ± 3.1	26
6j	42.2	NDd	NDd
6k	26.0	NDd	NDd
8	83.2	365.7 ± 63.2	202.9 ± 14.7
10	94.1	46.5 ± 5.6	45.6 ± 5.6	1
11	99.8	59.4 ± 4.2	10.1 ± 3.0	6
12	99.2	352.8 ± 28.8	2.4 ± 0.3	147

^aMeasured as a reduction in luciferase activity of BHK cells infected with YF-IRES-Luc at 50 μM in comparison to the control.

^bThe GI₅₀ is the concentration of the compound causing a 50% growth inhibition of uninfected BHK cells.

^cThe EC₅₀ is the concentration of the compound resulting in a 50% inhibition in virus production.

^dND indicates that the value was not determined; compounds that produced inhibitory activity of less than 50% in the preliminary screening test were considered to be inactive and their exact EC₅₀ and GI₅₀ values were not determined.